Why these trials matter

Long before omega‑3s became a household term, two massive clinical trials in Italy changed how cardiologists thought about heart health. The GISSI‑Prevenzione trial (1999) and its successor, GISSI‑HF (2008), tested a simple question: can 1 gram per day of EPA+DHA omega‑3s improve outcomes for people with serious heart conditions?

Together, these studies followed nearly 20,000 patients and produced some of the most influential findings in cardiovascular nutrition. Their results shaped guidelines, inspired decades of research, and still matter today — especially for older adults managing heart disease or heart failure.

GISSI‑Prevenzione (1999): Omega‑3s after a heart attack

This landmark trial enrolled 11,324 patients who had recently suffered a heart attack. Participants were randomly assigned to receive 1 gram/day of EPA+DHA or standard care alone. The study followed them for 3.5 years.

What the researchers found

• 20% reduction in all‑cause mortality
• 45% reduction in sudden cardiac death
• Benefits appeared within months

These results were striking. At the time, few interventions — even medications — showed this level of impact on sudden cardiac death. The findings suggested that omega‑3s may help stabilize heart rhythm and support healthier cardiac electrical activity.

Why this matters for older adults

Sudden cardiac death is more common with age, especially after a heart attack. The early benefits seen in GISSI‑Prevenzione made omega‑3s a widely recommended addition to post‑heart‑attack care for many years.

GISSI‑HF (2008): Omega‑3s for chronic heart failure

Nearly a decade later, researchers launched a second major trial — this time focusing on 6,975 patients with chronic heart failure. Unlike the earlier study, GISSI‑HF was double‑blind and placebo‑controlled, the gold standard for clinical research.

What the researchers found

• 9% reduction in all‑cause mortality
• 8% reduction in cardiovascular hospitalizations
• Benefits occurred on top of modern heart‑failure therapy

While the improvements were modest, they were meaningful — especially in a population with high risk and limited treatment options. The trial helped establish omega‑3s as a Class IIa recommendation in heart‑failure guidelines.

Why the results were so strong

Omega‑3s support heart health through several mechanisms:

• Anti‑arrhythmic effects — stabilizing cardiac electrical activity
• Anti‑inflammatory effects — reducing chronic vascular inflammation
• Improved endothelial function — helping blood vessels relax
• Better triglyceride regulation

These mechanisms help explain why benefits appeared early in GISSI‑Prevenzione and why heart‑failure patients in GISSI‑HF saw fewer hospitalizations.

What later studies found

Later omega‑3 trials have shown more mixed results. This is not unusual — modern patients often receive more aggressive medical therapy, leaving less room for additional benefit. Differences in dose, formulation, and population also influence outcomes.

But the GISSI trials remain foundational because they demonstrated that even a modest daily dose of omega‑3s can influence major cardiovascular outcomes in high‑risk patients.

What this means for older adults

These trials do not suggest that omega‑3s replace medications or cure heart disease. But they do show that a simple, well‑tolerated nutrient can support heart health in meaningful ways — especially after a heart attack or in chronic heart failure.

For most older adults, the most practical approach is a food‑first pattern that includes omega‑3–rich fish several times per week.

How to use this research in daily life

Eat omega‑3–rich fish regularly

• Salmon
• Sardines
• Trout
• Mackerel

Consider supplements only when appropriate

Supplements may be helpful for people who do not eat fish or who have specific medical needs, but they should be discussed with a clinician — especially for those on blood thinners or with heart‑rhythm conditions.

Focus on consistency

The benefits in both GISSI trials came from daily intake over years, not occasional use.

Key takeaways

• GISSI‑Prevenzione: 20% lower mortality and 45% lower sudden cardiac death.
• GISSI‑HF: 9% lower mortality and fewer hospitalizations.
• Benefits appeared early and were seen in nearly 20,000 patients.
• Omega‑3s support heart rhythm, inflammation, and vascular function.
• Food‑first omega‑3 intake is a practical, senior‑friendly strategy.

Reference

GISSI‑Prevenzione Investigators. Lancet. 1999;354:447–455.
GISSI‑HF Investigators. Lancet. 2008;372:1223–1230.